Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis

OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical study, OX640-002, evaluated both pharmacokinetic and pharmacodynamic effects of OX640 in subjects with and without allergic rhinitis.OX640 treatments achieved clinically relevant plasma levels of epinephrine more rapidly than the intramuscular reference product.Absorption from OX640 under allergic rhinitis conditions was significantly faster than under normal conditions, supporting rapid onset of effect also in patients with airway symptoms.View original content:https://www.prnewswire.co.uk/news-releases/orexo-announces-positive-topline-data-from-clinical-study-of-ox640-in-subjects-with-and-without-allergic-rhinitis-302347970.html